Rhumbline Advisers Csl LTD Transaction History

Rhumbline Advisers

$121 Billion
Q3 2025

A detailed history of Rhumbline Advisers transactions in Csl LTD stock. As of the latest transaction made, Rhumbline Advisers holds 13,049 shares of CSLLY stock, worth $756,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,049

Previous 16,579 21.29%

Holding current value

$756,320

Previous $1.31 Million 34.66%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 06, 2025	SELL	$64.07 - $88.99 $226,167 - $314,134	-3,530 Reduced 21.29%	13,049 $854,000
Q2 2025 Aug 12, 2025	SELL	$72.7 - $83.25 $8,433 - $9,657	-116 Reduced 0.69%	16,579 $1.31 Million
Q1 2025 Apr 08, 2025	SELL	$78.15 - $89.58 $8,752 - $10,032	-112 Reduced 0.67%	16,695 $1.32 Million
Q4 2024 May 29, 2025	BUY	$86.47 - $101.1 $9,684 - $11,323	112 Added 0.67%	16,807 $1.47 Million
Q4 2024 Jan 30, 2025	BUY	$86.47 - $101.1 $9,511 - $11,121	110 Added 0.66%	16,807 $1.47 Million

Q3 2024 Nov 12, 2024	BUY	$97.0 - $105.54 $102,335 - $111,344	1,055 Added 6.74%	16,697 $1.64 Million
Q2 2024 Aug 01, 2024	SELL	$86.82 - $98.5 $6,077 - $6,895	-70 Reduced 0.45%	15,642 $1.54 Million
Q1 2024 May 09, 2024	BUY	$89.91 - $99.41 $133,516 - $147,623	1,485 Added 10.44%	15,712 $1.48 Million
Q4 2023 Feb 08, 2024	BUY	$73.1 - $97.93 $30,775 - $41,228	421 Added 3.05%	14,227 $1.38 Million
Q3 2023 Nov 09, 2023	BUY	$80.15 - $92.62 $16,430 - $18,987	205 Added 1.51%	13,806 $1.11 Million
Q2 2023 Aug 08, 2023	BUY	$91.49 - $104.64 $1.24 Million - $1.42 Million	13,601 New	13,601 $1.25 Million

Others Institutions Holding CSLLY

# of Institutions

Shares Held

63.2K

Call Options Held

Put Options Held

View Full List

About CSL LTD

Ticker CSLLY
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 964,432,000
Market Cap $55.9B
Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plas...

More about CSLLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Csl LTD Transaction History